The global market for Lung Cancer Diagnostics is estimated at US$2.8 Billion in 2023 and is projected to reach US$4.7 Billion by 2030, growing at a CAGR of 7.8% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.
The growth in the lung cancer diagnostics market is driven by several factors, including technological innovations, an aging global population, increased awareness of lung cancer risks and symptoms, and healthcare system improvements. As diagnostic technology advances, the ability to detect lung cancer at earlier stages and the precision in understanding its molecular profile continue to improve, leading to more effective treatment strategies and better patient outcomes. Additionally, as the global population ages, the incidence of lung cancer increases, creating greater demand for diagnostic services. Public health initiatives and educational campaigns have also raised awareness about the signs and symptoms of lung cancer and the importance of early detection, leading more people to seek screening and diagnostics. Moreover, improvements in healthcare infrastructure, particularly in developing countries, expand access to advanced diagnostic tools, thus supporting market growth. Coupled with increasing healthcare expenditures and the expansion of health insurance coverage, these factors collectively drive significant developments in the lung cancer diagnostics sector, promising better management of this challenging disease.
The growth in the lung cancer diagnostics market is driven by several factors, including technological innovations, an aging global population, increased awareness of lung cancer risks and symptoms, and healthcare system improvements. As diagnostic technology advances, the ability to detect lung cancer at earlier stages and the precision in understanding its molecular profile continue to improve, leading to more effective treatment strategies and better patient outcomes. Additionally, as the global population ages, the incidence of lung cancer increases, creating greater demand for diagnostic services. Public health initiatives and educational campaigns have also raised awareness about the signs and symptoms of lung cancer and the importance of early detection, leading more people to seek screening and diagnostics. Moreover, improvements in healthcare infrastructure, particularly in developing countries, expand access to advanced diagnostic tools, thus supporting market growth. Coupled with increasing healthcare expenditures and the expansion of health insurance coverage, these factors collectively drive significant developments in the lung cancer diagnostics sector, promising better management of this challenging disease.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Imaging Tests segment, which is expected to reach US$2.3 Billion by 2030 with a CAGR of a 7.3%. The Sputum Cytology Tests segment is also set to grow at 7.8% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, estimated at $718.8 Million in 2023, and China, forecasted to grow at an impressive 11.3% CAGR to reach $1.1 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Lung Cancer Diagnostics Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Lung Cancer Diagnostics Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Lung Cancer Diagnostics Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players such as Myriad Genetics, Inc., F. Hoffmann-La Roche AG, Biocartis NV, and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Select Competitors (Total 48 Featured):
- Myriad Genetics, Inc.
- F. Hoffmann-La Roche AG
- Biocartis NV
- Epigenomics AG
- Biodesix, Inc.
- Exosome Diagnostics, Inc.
- Admera Health
- Dr Lal PathLabs Ltd.
- Guardant Health, Inc.
- Oncimmune Holding PLC
- Blueprint Genetics OY
- CellMax Life, Inc.
- Circulogene
- BGI Genomics Co Ltd.
- Inivata Ltd.
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARYIII. MARKET ANALYSISCANADAITALYSPAINRUSSIAREST OF EUROPESOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
UNITED KINGDOM
ASIA-PACIFIC
AUSTRALIA
INDIA
LATIN AMERICA
MIDDLE EAST
AFRICA
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Myriad Genetics, Inc.
- F. Hoffmann-La Roche AG
- Biocartis NV
- Epigenomics AG
- Biodesix, Inc.
- Exosome Diagnostics, Inc.
- Admera Health
- Dr Lal PathLabs Ltd.
- Guardant Health, Inc.
- Oncimmune Holding PLC
- Blueprint Genetics OY
- CellMax Life, Inc.
- Circulogene
- BGI Genomics Co Ltd.
- Inivata Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 605 |
| Published | November 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 2.8 Billion |
| Forecasted Market Value ( USD | $ 4.7 Billion |
| Compound Annual Growth Rate | 7.8% |
| Regions Covered | Global |
